Cancer Research Matters

Share

Translation tales - 20 years of forming spinouts

Season 1, Ep. 2

Steve Jackson is the University of Cambridge Frederick James Quick Professor of Biology. He is also Head of Cancer Research UK Laboratories at the Wellcome Trust/Cancer Research UK Gurdon Institute. Steve’s main academic work is in the field of DNA damage repair, but he also founded KuDOS Pharmaceuticals in order to translate and market the PARP inhibitor Olaparib/ Lynparza. He talks about the difference between academic and commercial science, tips for forming a spinout company and what we should aim for in the next 20 years of cancer research.


Further reading on the commercialisation of DNA repair inhibitors:

Article:

https://news.cancerresearchuk.org/2020/09/24/parp-inhibitors-halting-cancer-by-halting-dna-repair/

Paper:

https://www.nature.com/articles/nature03445


Explore how we can work with you to help translate your work



More Episodes

9/6/2022

Side effects and sub-types: 20 years of understanding childhood cancer

Season 1, Ep. 6
Cancer Research Matters, a new Podcast from Cancer Research UK featuring some of the incredible researchers behind cancer research. The idea is to drive and provoke conversation around cancer science, how it shapes our understanding of the disease and the challenges we face as we develop therapies. The first series focusses on the 20th anniversary of CRUK – we’ll be winding back the clock on some of the great discoveries and breakthroughs made in the past two decades and asking some leading names where they think we’ll be in another 20 years.This episode features Professor Richard Gilbertson. Richard is a paediatric oncology clinician scientist and is the Director of the Cancer Research UK Cambridge Centre. He has dedicated his career to understanding childhood brain tumours and is perhaps known best for his work identifying different types of medulloblastoma and ependymoma – two of the most common kinds of childhood brain tumour. He talks about the challenges and successes of the childhood cancer research community, how he sees the future of the field and some of the incredible breakthroughs his lab has made on childhood brain cancers.  Further reading WNT signalling and brain cancer https://link.springer.com/article/10.1007/s00401-012-0958-8 https://www.sciencedirect.com/science/article/pii/S1535610816300551 Read about CRUK’s data strategy https://news.cancerresearchuk.org/2022/07/07/joining-the-dots-how-our-new-research-data-strategy-will-unlock-the-power-of-big-data/See the data strategy https://www.cancerresearchuk.org/sites/default/files/cancer_research_uk_-_research_data_strategy.pdf